ObvioHealth is to launch a decentralised clinical trial to evaluate Anatara Lifesciences’ Gastrointestinal ReProgramming (GaRP) product in Australia.
The trial will evaluate the safety and efficacy of the product for participants with irritable bowel syndrome–diarrhoea (IBS-D) subtype.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GaRP is a microbiome-targeted multi-component complementary medicine, which aims to address the underlying factors related to chronic gastrointestinal conditions that include irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
The randomised, double-blind, placebo-controlled trial will use a combination of in-home data collection methods, which will reduce or eliminate the need for follow-up visits to clinics.
Patients will use ObvioHealth’s easy-to-use smartphone application to report the severity of IBS-D symptoms, as well as the anticipated relief, quality of life, treatment adherence and changes in health status.
The ObvioHealth platform will gather all the data from the application and allow the research team to monitor the changes in real-time and quickly detect possible adverse events, as well as issues with protocol adherence.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAnatara Lifesciences CEO Steve Lydeamore said: “IBS impacts around one in five Australians at some point in their life with no current definitive cure.
“It is anticipated that GaRP’s mechanism of action will relieve symptoms of IBS-D by reducing inflammation and assisting repair of the gut lining, positively influencing the homeostasis and metabolites of the microbiome.”
During the clinical trial, a study nurse will pay in-home visits to measure vitals and collect samples.
The use of ObvioHealth’s technology helps in virtual data collection and supports enrolment for the study anywhere in Australia and diversifying the study population.
In March, ObvioHealth announced the launch of a Phase II/III study of RedHill Biopharma’s RHB-107 (upamostat) in the US for the treatment of Covid-19.
